1887
Rapid communication Open Access
Like 0

Abstract

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65–79-year-olds and 13% (95% CI: −15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.41.17-00645
2017-10-12
2024-11-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2017.22.41.17-00645
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/41/eurosurv-22-41-2.html?itemId=/content/10.2807/1560-7917.ES.2017.22.41.17-00645&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC) / World Health Organization Regional Office for Europe (WHO/Europe). Joint ECDC-WHO/Europe weekly influenza update - Week 20/2017 (15 – 21 May 2017). ECDC-WHO/Europe. [Accessed 20 Jun 2017]. Available from: https://flunewseurope.org/Archives
  2. European Centre for Disease Prevention and Control (ECDC). Risk assessment of seasonal influenza, EU/EEA, 2016-2017 - Update. Stockholm: ECDC; 25 Jan 2017. Available from: http://ecdc.europa.eu/en/publications/Publications/Risk-assessment-seasonal-influenza-2016-2017-update.pdf
  3. Kissling E, Rondy MI-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7):30464. . https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464  PMID: 28230524 
  4. Integrated Monitoring of Vaccines in Europe plus (I-MOVE+). [Internet]. [Accessed 10 October 2017]. Available from: http://www.i-moveplus.eu/wp2
  5. Rondy M, Larrauri A, Casado I, Alfonsi V, Pitigoi D, Launay O, et al. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Euro Surveill. 2017;22(30):30580.  https://doi.org/10.2807/1560-7917.ES.2017.22.30.30580  PMID: 28797322 
  6. McNeil SA, Andrew MK, Ye L, Haguinet F, Hatchette TF, ElSherif M, et al. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill. 2015;20(5):21024.  https://doi.org/10.2807/1560-7917.ES2015.20.5.21024  PMID: 25677052 
  7. Puig-Barbera J, Mira-Iglesias A, Tortajada-Girbes M, Lopez-Labrador FX, Belenguer-Varea A, Carballido-Fernandez M, et al. Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results. Euro Surveill. 2015;20(8):21044.  https://doi.org/10.2807/1560-7917.ES2015.20.8.21044  PMID: 25742432 
  8. Rondy M, Puig-Barbera J, Launay O, Duval X, Castilla J, Guevara M, et al. 2011-12 seasonal influenza vaccines effectiveness against confirmed A(H3N2) influenza hospitalisation: pooled analysis from a European network of hospitals. A pilot study. PLoS One. 2013;8(4):e59681.  https://doi.org/10.1371/journal.pone.0059681  PMID: 23565159 
  9. Rondy M, El Omeiri N, Thompson MG, Levêque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017;•••:S0163-4453(17)30299-2.; Epub ahead of print.  https://doi.org/10.1016/j.jinf.2017.09.010  PMID: 28935236 
  10. Melidou A, Broberg EEuropean region influenza surveillance network. Predominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe - Contribution of surveillance data from World Health Organization (WHO) European Region to the WHO vaccine composition consultation for northern hemisphere 2017/18. Vaccine. 2017;35(37):4828-35.  https://doi.org/10.1016/j.vaccine.2017.07.057  PMID: 28780977 
  11. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Geneva: WHO; 1 Mar 2017. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/
  12. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2018 southern hemisphere influenza season. Geneva: WHO; 28 Sep 2017. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2018_south/en/
  13. World Health Organization (WHO). Influenza Update N°299. Geneva: WHO; 2 Oct 2017. Available from: http://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en
/content/10.2807/1560-7917.ES.2017.22.41.17-00645
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error